Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-34a
- Development stage
- Preclinical
- Lead developer
- Viridian Therapeutics
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Anti-miR-34a (also known as miR-34a inhibitor or antimiR-34a) is a class of synthetic antisense oligonucleotides designed to target and inhibit microRNA-34a (miR-34a). MiR-34a is a key post-transcriptional regulator that is aberrantly elevated in metabolic disorders, obesity, and cardiovascular diseases. By binding complementarily to mature miR-34a, anti-miR-34a prevents it from suppressing its target genes, such as SIRT1, NAMPT, and beta-klotho (KLB). In preclinical models of obesity and metabolic dysfunction-associated steatohepatitis (MASH), inhibition of miR-34a restores NAD+ levels, enhances SIRT1 activity, improves FGF19/FGF21 signaling, and alleviates hepatic steatosis, inflammation, and glucose intolerance. Additionally, anti-miR-34a has been investigated for its potential to attenuate cardiac remodeling, hypertrophy, and fibrosis in cardiovascular disease models.
- Other names
- antagomir-34aantagomir34aantagomir 34aanti-miR34aanti-miR-34aanti-miR 34aantimiR-34aantimiR34aantimiR 34amicroRNA-34a antagonistmicroRNA34a antagonistmicroRNA 34a antagonistmicroRNA-34a inhibitormicroRNA34a inhibitormicroRNA 34a inhibitormiR-34a inhibitormiR34a inhibitormiR 34a inhibitor
Beyond the preview
Go deeper on anti-miR-34a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-34a.